Tamoxifen as a potential treatment of glioma.

abstract：:Long lasting occupational exposure to asbestos dust may cause skin corns, benign pleural effusion, hyaline plaques of the parietal pleura, diffuse thickening of the pulmonary pleura, and asbestosis, i.e. diffuse interstitial pulmonary fibrosis. Malignant disorders include lung cancer and mesothelioma of the pleura, pe...

journal_title：Anti-cancer drugs

authors： Gruber UF

更新日期：1990-12-01 00:00:00

abstract：:This trial aimed to define a recommended safe dose (RSD) of weekly paclitaxel and irinotecan combined with carboplatin in patients with advanced cancer. Patients with advanced cancer were eligible for this trial. Dose-limiting toxicity (DLT) was considered to be any grade greater than or equal to 3 (G> or =3) nonhemat...

journal_title：Anti-cancer drugs

authors： Briasoulis E,Golfinopoulos V,Karina M,Papakostas P,Pavlidis N,Fountzilas G

更新日期：2010-09-01 00:00:00

abstract：:Previously, we synthesized a series of hydrazide class of compounds and examined their cytotoxicity in a number of cancer cell lines. Among these analogues, SC144 exhibited potent cytotoxicity against a panel of drug-sensitive and drug-resistant cancer cell lines. To further explore its therapeutic potentials in the c...

journal_title：Anti-cancer drugs

authors： Oshima T,Cao X,Grande F,Yamada R,Garofalo A,Louie S,Neamati N

更新日期：2009-06-01 00:00:00

abstract：:In this study, we tried to define in vitro interactions of two antitumor agents that have different sites and different mechanisms of action. Vinblastine (VLB) in combination with human recombinant interferon-alpha A/D (rHuIFN-alpha A/D) and in combination with murine recombinant interferon-gamma (rMuIFN-gamma) was st...

journal_title：Anti-cancer drugs

authors： Jezersek B,Novaković S,Sersa G,Auersperg M,Fleischmann WR Jr

更新日期：1994-02-01 00:00:00

abstract：:The mechanism of action of a synthetic compound--2,2'-bipyridyl-6-carbothioamide--was investigated by developing tumor lines resistant to it (P388-R1.5 and P388-R4). P388-R4 is resistant to inhibitors of ribonucleotide reductase (RR) while no resistance was observed to antitumor drugs having other targets (except to b...

journal_title：Anti-cancer drugs

authors： Nocentini G,Federici F,Armellini R,Franchetti P,Barzi A

更新日期：1990-12-01 00:00:00

abstract：:The antitumor effect of etoposide (ETO) may be related to duration of exposure to a relatively low serum level while myelosuppression may be dependent on peak ETO serum levels. With regard to such therapeutic ranges, duration of exposure to predefined plasma ETO concentration ranges and the related AUC (expressed as p...

journal_title：Anti-cancer drugs

authors： Würthwein G,Krümpelmann S,Tillmann B,Real E,Schulze-Westhoff P,Jürgens H,Boos J

更新日期：1999-10-01 00:00:00

abstract：:A phase I/II study to determine the recommended dose for combination therapy with CPT-11 (irinotecan hydrochloride) and S-1 (tegafur, gimestat and otastat potassium) for advanced or recurrent gastric cancer, and to assess the safety and efficacy of this therapy. In the phase I portion of the study, S-1 was administere...

journal_title：Anti-cancer drugs

authors： Katsube T,Ogawa K,Ichikawa W,Fujii M,Tokunaga A,Takagi Y,Kochi M,Hayashi K,Kubota T,Aiba K,Arai K,Terashima M,Kitajima M

更新日期：2007-06-01 00:00:00

abstract：:We examined the anti-tumor activity and structure-activity requirements of omega-hydroxy fatty acids (omega-HFAs) on the human melanoma cell line G361. The omega-hydroxystearic acid (omega-HSA) had strong growth-inhibiting and cytotoxic activity. Although omega-hydroxypalmitic acid (omega-HPA) also had growth-inhibiti...

journal_title：Anti-cancer drugs

authors： Abe A,Sugiyama K

更新日期：2005-06-01 00:00:00

abstract：:Acquired docetaxel (Doc) resistance in hormone-refractory prostate cancer (HRPC) remains an ongoing clinical challenge, resulting in failed chemotherapy and tumor recurrence. However, the mechanism of Doc-resistance development in prostate cancer cells is still unclear. Here, we observed a subpopulation of prostate ca...

journal_title：Anti-cancer drugs

authors： Qiu S,Deng L,Bao Y,Jin K,Tu X,Li J,Liao X,Liu Z,Yang L,Wei Q

更新日期：2018-10-01 00:00:00

abstract：:Four novel 4-substituted 5-nitrophthalimides (5-substituted-6-nitro-1,3-dihydro-isoindol-1,3-diones), 6, 7, 10 and 11, and the known 5 are prepared as analogs of the dinitrobenzamide prodrug CB 1954, 1, and considered as potential candidates for gene-directed enzyme prodrug therapy. All the phthalimides are poor subst...

journal_title：Anti-cancer drugs

authors： Mehta LK,Hobbs S,Chen S,Knox RJ,Parrick J

更新日期：1999-09-01 00:00:00

abstract：:Lung cancer is considered the number one killer among all cancers. Recent observations have altered the treatment paradigm for non-small-cell lung cancer (NSCLC). The discovery of activating mutations in the epidermal growth factor receptor and anaplastic lymphoma kinase positivity has made personalized treatment for ...

journal_title：Anti-cancer drugs

authors： Petrosyan F,Daw H,Haddad A,Spiro T

更新日期：2012-11-01 00:00:00

abstract：:α-Lipoic acid (α-LA) is a biogenic antioxidant that has been used successfully in the treatment of diabetic polyneuropathy and its application to many oxidative stress-associated chronic diseases has increased. In this study, we investigated the effect of α-LA on colorectal cancer cell growth and its underlying mechan...

journal_title：Anti-cancer drugs

authors： Yoo TH,Lee JH,Chun HS,Chi SG

更新日期：2013-07-01 00:00:00

abstract：:Thirty-three patients with advanced and refractory breast cancer were treated with two mitoxantrone-containing regimens (mitoxantrone plus mitomycin and mitoxantrone plus mitomycin plus methotrexate). All patients had received previous chemotherapy with cyclophosphamide, methotrexate and fluorouracil (CMF); cyclophosp...

journal_title：Anti-cancer drugs

authors： Astone A,Cassano A,Fontana T,Noviello MR,Pozzo C,Barone C

更新日期：1992-10-01 00:00:00

abstract：:Thrombin is a potent mitogen for many tumor cells, suggesting that this enzyme may be involved in tumor genesis and metastasis. Inhibition of thrombin expressed on the surface of tumor cells may improve outcomes in some tumor cases. For this reason, a thrombin inhibitor to be applied in antitumor therapy must have fav...

journal_title：Anti-cancer drugs

authors： López ML,Nowak G

更新日期：2004-02-01 00:00:00

abstract：:A 1-year complete remission could be achieved with high-dose systemic chemotherapy in a 33-year-old patient with relapsed germ cell tumor presenting with leptomeningeal carcinomatosis (LC). Although LC in general has a very poor prognosis for patients with chemosensitive malignancies, systemic chemotherapy should be c...

journal_title：Anti-cancer drugs

authors： Denissen NH,van Spronsen DJ,Smilde TJ,De Mulder PH

更新日期：2005-09-01 00:00:00

abstract：:The tetracycline family includes tetracycline, doxycycline and minocycline, all of which have been used as antibiotics effectively for decades. New uses emerged for these compounds after their effect on mitochondrial function was discovered. Cytostatic and cytotoxic activity of these compounds was shown against cell l...

journal_title：Anti-cancer drugs

authors： Saikali Z,Singh G

更新日期：2003-11-01 00:00:00

abstract：:ET-743 is a marine anti-cancer drug and is currently in phase I trials in which the effect of combination therapies will be investigated. Its dose-limiting toxicity in patients is hepatotoxicity. In-vitro studies have shown that ET-743 is mainly metabolized by cytochrome P450 (CYP) 3A4, but also by 2C9, 2C19, 2D6 and ...

journal_title：Anti-cancer drugs

authors： Brandon EF,Meijerman I,Klijn JS,den Arend D,Sparidans RW,Lázaro LL,Beijnen JH,Schellens JH

更新日期：2005-10-01 00:00:00

abstract：:Response rates reported in early phase II clinical trials are often not reproduced in subsequent larger or phase III studies. Independent review of claimed partial or complete responders to gemcitabine was undertaken in four pivotal, open-label phase II studies of advanced, non-small cell lung cancer (NSCLC) to provid...

journal_title：Anti-cancer drugs

authors： Gwyther SJ,Aapro MS,Hatty SR,Postmus PE,Smith IE

更新日期：1999-09-01 00:00:00

abstract：:Human colon cancer SW480 cells express the c-myc gene. On the other hand, SW480DDP cell lines resistant to cisplatin exhibited decreased c-myc gene expression, but their cell growth rates remained similar to those of their parental cells. Antisense oligonucleotides to c-myc inhibited c-myc expression and induced incre...

journal_title：Anti-cancer drugs

authors： Funato T,Kozawa K,Kaku M,Sasaki T

更新日期：2001-11-01 00:00:00

abstract：:Protein phosphatase 2A (PP2A) is a new target for platinum (Pt)-based cancer chemotherapeutic agents. A series of novel Pt complexes containing demethylcantharidin, a modified component of a traditional Chinese medicine (TCM), [Pt(C8H8O5)(NH2R)2] 1-5 have been shown to inhibit PP2A both in its purified form and in cel...

journal_title：Anti-cancer drugs

authors： To KK,Ho YP,Au-Yeung SC

更新日期：2005-09-01 00:00:00

abstract：:Apalutamide (ARN-509) is an antiandrogen that binds selectively to androgen receptors (AR) and does not show antagonist-to-agonist switch like bicalutamide. We compared the activity of ARN versus bicalutamide on prostate cancer cell lines. The 22Rv1, PC3, and DU145 cell lines were used to study the effect of ARN and b...

journal_title：Anti-cancer drugs

authors： Koukourakis MI,Kakouratos C,Kalamida D,Mitrakas A,Pouliliou S,Xanthopoulou E,Papadopoulou E,Fasoulaki V,Giatromanolaki A

更新日期：2018-04-01 00:00:00

abstract：:An i.v. formulation of rubitecan (9-nitrocamptothecin) was evaluated in five human solid tumor xenograft models. Rubitecan in IDD-P, a particulate suspension of the insoluble analog, produced significant tumor growth delay in athymic nude mice bearing A375 melanoma, and MX-1 breast, SKMES non-small-cell lung, Panc-1 p...

journal_title：Anti-cancer drugs

authors： Sands H,Mishra A,Stoeckler JD,Hollister B,Chen SF

更新日期：2002-10-01 00:00:00

abstract：:Pancreatic and biliary tract carcinomas are very chemoresistant. After a first-line treatment with a gemcitabine-based regimen, no second-line scheme is consolidated in clinical practice. The aim of this study was to evaluate the toxicity and the activity of the FOLFIRI regimen as first-line or second-line chemotherap...

journal_title：Anti-cancer drugs

authors： Moretto R,Raimondo L,De Stefano A,Cella CA,Matano E,De Placido S,Carlomagno C

更新日期：2013-10-01 00:00:00

abstract：:Our previous studies have demonstrated the in-vitro and in-vivo targeting of a generation-5 (G5) dendrimer-based multifunctional conjugate, which used folic acid (FA) as the targeting agent and methotrexate (MTX) as the chemotherapeutic drug. For the synthesized G5-FA-MTX nanodevice conjugate to be clinically applicab...

journal_title：Anti-cancer drugs

authors： Myc A,Douce TB,Ahuja N,Kotlyar A,Kukowska-Latallo J,Thomas TP,Baker JR Jr

更新日期：2008-02-01 00:00:00

abstract：:Aberrant expression of the epidermal growth factor receptor (EGFR) system has been reported in a wide range of epithelial cancers. In some studies, this has also been associated with a poor prognosis and resistance to the conventional forms of therapies. These discoveries have led to the strategic development of sever...

journal_title：Anti-cancer drugs

authors： Modjtahedi H,Essapen S

更新日期：2009-11-01 00:00:00

abstract：:Epidemiological and clinical studies suggesting a significant inverse relationship between intake of dietary selenium and overall cancer risk have led to initiation of a randomized, placebo-controlled, phase III clinical trial testing the safety and efficacy of selenized yeast as a chemopreventive agent for prostate c...

journal_title：Anti-cancer drugs

authors： Stratton MS,Reid ME,Schwartzberg G,Minter FE,Monroe BK,Alberts DS,Marshall JR,Ahmann FR

更新日期：2003-09-01 00:00:00

abstract：:To investigate whether mammalian DNA topoisomerase II is directly involved in recombination events, the effects of ICRF-193, a specific catalytic inhibitor on sister chromatid exchange (SCE), were examined in MR-6 cells. ICRF-193 only slightly elevated SCE formation after 3 or 44 h treatments, while VP-16, a cleavable...

journal_title：Anti-cancer drugs

authors： Hamatake M,Andoh T,Ishida R

更新日期：1997-07-01 00:00:00

abstract：:The main aim of this study is to assess the safety and antitumor efficacy of a palladium(II) (Pd)-saccharinate complex with terpyridine. To characterize the Pd(II) complex in vitro, its cytotoxicity was evaluated using a water-soluble tetrazolium salt cell viability assay and the mechanism of cell death was assessed b...

journal_title：Anti-cancer drugs

authors： Cetin Y,Adiguzel Z,Polat HU,Akkoc T,Tas A,Cevatemre B,Celik G,Carikci B,Yilmaz VT,Ulukaya E,Acilan C

更新日期：2017-09-01 00:00:00

abstract：:The cytotoxic effects of Tomudex (TX) were investigated on a panel of 15 human tumor cell lines expressing a spontaneous sensitivity to the tested agent. We determined the basal cellular amount of relevant cellular factors potentially related to the cytotoxic efficacy of or resistance to TX. We selected thymidylate sy...

journal_title：Anti-cancer drugs

authors： Chéradame S,Chazal M,Fischel JL,Formento P,Renée N,Milano G

更新日期：1999-06-01 00:00:00

abstract：:Management of gastric cancer in older adults is challenging. Perioperative treatment with epirubicin, cisplatin, and 5-fluorouracil combination chemotherapy and surgery is considered the standard treatment of locally advanced gastric adenocarcinoma. However, this chemotherapy regimen is not well tolerated in older adu...

journal_title：Anti-cancer drugs

authors： Amini A,Sanati H

更新日期：2011-11-01 00:00:00